RABV antigenic peptide loaded polymeric nanoparticle production, characterization, and preliminary investigation of its biological activity

Basit Öğe Kaydı
dc.authorid0000-0002-6662-6642
dc.authorid0000-0002-7176-4484
dc.authorid0000-0002-4276-1559
dc.contributor.authorBezir, Kubra
dc.contributor.authorArayici, Pelin Pelit
dc.contributor.authorAkgul, Busra
dc.contributor.authorAbamor, Emrah Sefik
dc.contributor.authorAcar, Serap
dc.date.accessioned2026-02-08T15:15:37Z
dc.date.available2026-02-08T15:15:37Z
dc.date.issued2025
dc.departmentBursa Teknik Üniversitesi
dc.description.abstractNanoparticle-based antigen carrier systems have become a significant area of research with the advancement of nanotechnology. Biodegradable polymers have emerged as particularly promising carrier vehicles due to their ability to address the limitations of existing vaccine systems. In this study, we successfully encapsulated the G5-24 linear peptide, located between amino acids 253 and 275 in the primary sequence of the rabies virus G protein, into biodegradable and biocompatible PLGA copolymer using the double emulsion solvent evaporation method. The resulting nanoparticles had a size of approximately 230.9 +/- 0.9074 nm, with a PDI value of 0.168 +/- 0.017 and a zeta potential value of -9.86 +/- 0.132 mV. SEM images confirmed that the synthesized nanoparticles were uniform in size and distribution. Additionally, FTIR spectra indicated successful peptide loading into the nanoparticles. The encapsulation efficiency of the peptide-loaded nanoparticles was 73.3%, with a peptide loading capacity of 48.2% and a reaction yield of 30.4%. Peptide release studies demonstrated that 65.55% of the peptide was released in a controlled manner over 28 d, following a 'biphasic burst release' profile consistent with the degradation profile of PLGA. This controlled release is particularly beneficial for vaccine studies. Cytotoxicity tests revealed that the R-NP formulation did not induce cytotoxicity in fibroblast cells and enhanced NO production in macrophages, indicating its potential for vaccine development.
dc.identifier.doi10.1088/1361-6528/ad84fe
dc.identifier.issn0957-4484
dc.identifier.issn1361-6528
dc.identifier.issue2
dc.identifier.pmid39383880
dc.identifier.scopus2-s2.0-85206959969
dc.identifier.scopusqualityQ1
dc.identifier.urihttps://doi.org/10.1088/1361-6528/ad84fe
dc.identifier.urihttps://hdl.handle.net/20.500.12885/5873
dc.identifier.volume36
dc.identifier.wosWOS:001335508700001
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherIop Publishing Ltd
dc.relation.ispartofNanotechnology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzWOS_KA_20260207
dc.subjectrabies
dc.subjectpeptide delivery
dc.subjectPLGA nanoparticles
dc.subjectvaccine
dc.subjectnitric oxide
dc.titleRABV antigenic peptide loaded polymeric nanoparticle production, characterization, and preliminary investigation of its biological activity
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu